Hans Schikan

Swanbridge Capital is a Rotterdam based venture capital fund actively investing in young, high potential companies active in the field of therapeutics, diagnostics and medical devices. We are committed to invest in companies that are in a very early stage of development and still need to generate Proof of Concept for their technology. Our investments go beyond financial investments since we work very closely with our portfolio companies and take an active role in their business processes. For more information visit www.swanbridgecapital.nl

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

The Dutch Life Sciences & Health (LSH) sector is one of ten “top sectors” in the Netherlands and part of the Dutch government’s Mission-driven Top Sectors and Innovation Policy. The top sectors are designated by the Ministry of Economic Affairs and Climate Policy and are selected on their ability to contribute substantially to global societal challenges. Under the guidance of Top Sector Life Sciences & Health (Health~Holland) public and private partners combine nationally their investments and activities to gain economic and societal impact for Health & Care, one of the four challenges of the Dutch government's Mission-driven Innovation Policy. The common focus of the partners is formed by five Health & Care missions as formulated by the Ministry of Health, Welfare and Sport (VWS). The central mission is as follows: By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socioeconomic groups will have decreased by 30%. There are four underlying missions that contribute to this central mission through changes to lifestyle and living environment, offering more care in the right place and better perspectives for people with chronic diseases, lifelong disabilities and dementia. Furthermore, we support the economic opportunities within this societal theme. In order to realise its central mission, Top Sector LSH stimulates, facilitates and finances a variety of public-private partnerships (PPPs), thematic and programmatic collaborations between quadruple helix organisations. By attracting financial means, supporting businesses, sharing best practices and the univocal (inter)national Health~Holland sector communication, the Top Sector builds on the strengths of the Dutch LSH sector.

Biotech fund

Swanbridge Capital is a Rotterdam based venture capital fund actively investing in young, high potential companies active in the field of therapeutics, diagnostics and medical devices. We are committed to invest in companies that are in a very early stage of development and still need to generate Proof of Concept for their technology. Our investments go beyond financial investments since we work very closely with our portfolio companies and take an active role in their business processes. For more information visit www.swanbridgecapital.nl

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

The Dutch Life Sciences & Health (LSH) sector is one of ten “top sectors” in the Netherlands and part of the Dutch government’s Mission-driven Top Sectors and Innovation Policy. The top sectors are designated by the Ministry of Economic Affairs and Climate Policy and are selected on their ability to contribute substantially to global societal challenges. Under the guidance of Top Sector Life Sciences & Health (Health~Holland) public and private partners combine nationally their investments and activities to gain economic and societal impact for Health & Care, one of the four challenges of the Dutch government's Mission-driven Innovation Policy. The common focus of the partners is formed by five Health & Care missions as formulated by the Ministry of Health, Welfare and Sport (VWS). The central mission is as follows: By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socioeconomic groups will have decreased by 30%. There are four underlying missions that contribute to this central mission through changes to lifestyle and living environment, offering more care in the right place and better perspectives for people with chronic diseases, lifelong disabilities and dementia. Furthermore, we support the economic opportunities within this societal theme. In order to realise its central mission, Top Sector LSH stimulates, facilitates and finances a variety of public-private partnerships (PPPs), thematic and programmatic collaborations between quadruple helix organisations. By attracting financial means, supporting businesses, sharing best practices and the univocal (inter)national Health~Holland sector communication, the Top Sector builds on the strengths of the Dutch LSH sector.

Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. Our mission is to deliver impactful medicines and solutions for a healthier every day. This site is intended for residents of the United States and its territories. You are reminded to protect yourself against recruiting fraud from individuals, organizations or other entities claiming to represent Organon. All official Organon recruitment emails will come from accounts formatted as name@organon.com or organon@workday.com, and Organon will never conduct interviews by chat or email, or make job offers through social media or online forums. All candidates for roles at Organon will first meet with a recruiter and interview team, via Teams or in person. Organon will never ask you to make financial transactions on its behalf or ask you to receive or ship packages or goods. For more information on adverse event reporting, visit http://bit.ly/AEReporting. To read our community guidelines, visit http://bit.ly/OrganonCommunityGuidelines. Follow us on Twitter at Organon (@OrganonLLC). Follow us on Instagram at Organon (@OrganonLLC).